The First Non-Invasive, Inexpensive, Mobile,
Early Disease Screening and Monitoring Platform
Forward-Looking Statements
This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that
involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results
expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things statements
with respect to our objectives and strategies to achieve those objectives, as well as statements with respect to our beliefs, plans,
expectations, anticipations, estimates or intentions. Such forward-looking statements may also include statements, among other
things, concerning the efficacy, safety and intended utilization of Vantage’s product candidates, the conduct and results of future clinical
trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may
cause actual results to differ materially include, among others, the risk that product candidates that appeared promising in early
research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty
enrolling, Vantage may not obtain approval to market its product candidates, or outside financing may not be available to meet capital
requirements. These forward-looking statements are based on our current expectations. We caution that all forward-looking
information is inherently uncertain and actual results may differ materially from the assumptions, estimates or expectations reflected or
contained in the forward-looking information, and that actual future performance will be affected by a number of factors, including
economic conditions, technological change, regulatory change and competitive factors, many of which are beyond our control.
Therefore, future events and results may vary significantly from what we currently foresee.
For a further list and description of the risks and uncertainties the Company faces, please refer to the Company’s most recent 3/31 Form
10-Q and 6/30 Form 10-K and other filings Vantage files with the Securities and Exchange Commission and are available at www.sec.gov.
Such forward-looking statements are current only as of the date they are made, and Vantage assumes no obligation to update any
forward-looking statements contained in this presentation whether as a result of new information, future events or otherwise.
COPYRIGHT VANTAGE MHEALTHCARE 2015
2
The Vantage Sensor – reducing healthcare costs
while improving patient outcomes
COPYRIGHT VANTAGE MHEALTHCARE 2015
3
The following presentation by Vantage mHealthcare will
introduce disruptive technology which is state of the art
in early cancer screening by simply using human breath!
It was developed and patented by NASA to monitor the atmosphere in
the Space Shuttle. It is currently being used on the International Space
Station for atmosphere security, the Mars Curiosity Rover to analyze
the atmosphere of Mars, and by the Department of Homeland Security
and the Department of Defense.
COPYRIGHT VANTAGE MHEALTHCARE 2015
4
Vantage Vision - Healthcare
To save lives and reduce health care costs through early disease screening
COPYRIGHT VANTAGE MHEALTHCARE 2015
5
Vantage Mission - Healthcare
To commercialize mobile breath sensor technologies that enable
Health Care Providers (HCP) to better manage the health care
continuum from managing illness to managing wellness
COPYRIGHT VANTAGE MHEALTHCARE 2015
6
Vantage Partnerships
COPYRIGHT VANTAGE MHEALTHCARE 2015
7
Problem
§ There more deaths from Lung
Cancer than from Prostate,
Pancreas, Breast and Colon
combined
§ Only 15 percent of lung cancer
cases are screened at an early
stage -- 85 percent are not
COPYRIGHT VANTAGE MHEALTHCARE 2015
Source: American Cancer Society
Facts and Figures
8
The Problem
§ The five-year survival rate for
lung cancer is 67 percent for cases
detected early or when the
disease is still localized
§ For distant tumors (spread to
other organs), stage IV, the fiveyear survival rate is only 2.5
percent
§ That’s why over half of people
with lung cancer die within one
year of being diagnosed
COPYRIGHT VANTAGE MHEALTHCARE 2015
Source: Jyotindra Sing Nizams Institute
of Medical Science (NIMS)
9
The Problem
COPYRIGHT VANTAGE MHEALTHCARE 2015
10
The Problem
§ Lung Cancer incidence in China per
100,000 people is the highest of
the countries surveyed
§ Lung Cancer incidence in India per
100,000 people is the lowest of the
countries surveyed
§ Females in the USA have the
highest incidence of lung cancer of
the countries surveyed
COPYRIGHT VANTAGE MHEALTHCARE 2015
Source: source Jyotindra Sing Nizams
Institute of Medical Science (NIMS)
11
An Existing Solution
The U.S. Preventive
Services Task Force has
recommended low-dose
CT scans for high risk
patients age 55 to 79
§ NIH funded study recommends older
persons with ‘lengthy history of
moderate smoking’ undergo annual
low-dose CT scans
§ Screenings would avert 521 deaths
per 100,000 smokers but cause 24
deaths per 100,000 smokers as result
of radiation exposure and the many
“false positives” the scans produce
§ Out of pocket cost for these
screenings is $100 to $350 — not
covered by all insurance companies
COPYRIGHT VANTAGE MHEALTHCARE 2015
12
Our Solution to the Unmet Need
§ Non-invasive, no side effects
Works with multiple
devices
§ Works with any smartphone,
tablet or laptop
§ Self-flushes after each use enabling
access to another application or
screening of another patient
§ Monthly cost to HCP will be very
low per month per application
COPYRIGHT VANTAGE MHEALTHCARE 2015
13
Our Solution to the Unmet Need
ü“Just Breathe” – screening takes
place with a simple breath exhale at
the HCP office, clinic, hospital or
pharmacy.
üResults are automatically shown on
the screen and can be evaluated by
the HCP instantly in real time
üThe one time cost of the sensor will
be reasonable for HCP
COPYRIGHT VANTAGE MHEALTHCARE 2015
14
Our Solution to the Unmet Need
üThe results appear on the HCP’s
smartphone, tablet or laptop in real
time
üThe results can also be emailed
directly to the HCP to be maintained
for future comparison
üIn the future the results will able to be
incorporated directly into the
patients electronic medical record
COPYRIGHT VANTAGE MHEALTHCARE 2015
15
Behind the Technology
COPYRIGHT VANTAGE MHEALTHCARE 2015
16
Our Solution to the Unmet Need
COPYRIGHT VANTAGE MHEALTHCARE 2015
17
The Sensor Delivers Great Value to Patients
Higher
Survival
Rate
With
Early
Screening
COPYRIGHT VANTAGE MHEALTHCARE 2015
Less Pain
Suffering
and Cost
When
Discovered
Early
18
The Sensor Delivers Great Value
To Payors and Providers
Health
cost
driven
down
for
payors
COPYRIGHT VANTAGE MHEALTHCARE 2015
HCP
achieves
better
outcomes
for
Patients
at a low
cost
19
The HCP will be able to do
screenings from all patients
from one Sensor because the
disposable filter prevents
contamination between
patients
The HCP can download
different Apps (as they
become available)
and pay a monthly fee
for each app used
There will be package deals
for multiple apps
COPYRIGHT VANTAGE MHEALTHCARE 2015
The very same sensor will also be able to
detect the following using different
applications*:
§
Breast cancer
§
Colorectal cancer
§
Prostate cancer
§
Narcotics whether legal or illegal
§
Medical Adherence - whether you are taking the
medications prescribed by your doctor
§
Strep Throat and COPD
§
Infectious diseases such as tuberculosis and HIV/AIDS
§
Other cancers and disease states
* not necessarily in this order
20
Behind the Technology
Before the Vantage
Sensor, NASA
scientists used the
sensor technology
to test and protect
the Astronauts
from harmful
chemicals
COPYRIGHT VANTAGE MHEALTHCARE 2015
21
Behind the Technology
The NASA sensor technology offers nine years of results
Space Shuttle
COPYRIGHT VANTAGE MHEALTHCARE 2015
International Space Station
22
Behind the Technology
The Vantage Sensor was Awarded the
NASA Invention of the Year on April 13, 2013.
COPYRIGHT VANTAGE MHEALTHCARE 2015
23
Behind the Technology
Volatile organic compounds (VOCs) are organic chemicals that have
a high vapor pressure at ordinary, room-temperature conditions.
Their high vapor pressure results causes large numbers of molecules
to evaporate or sublimate from the liquid or solid form of the
compound and enter the surrounding air.
The exhaled human breath contains a few hundred volatile organic
compounds and is used in breath analysis to serve as a VOC
biomarker to test for marijuana and other legal or illegal drugs.
COPYRIGHT VANTAGE MHEALTHCARE 2015
24
Behind the Technology
• As
the vapor that makes up
your breath enters the sensor
a Breath Print is established
• Just
as a finger print is
unique to every person your
Breath Print has a signature
• Breath
has a variety of
biomarkers indicating various
legal and illegal drugs
COPYRIGHT VANTAGE MHEALTHCARE 2015
25
Behind the Technology
Studies have validated detection of the earliest stages of diseases
such as various types of cancer through exhaled breath however it is
not practical for the population as a whole to go to a location where
a mass spectrometer is located
In addition, the cost of such a test is very high, typically not covered
by any insurance and has HIPPA issues
The proprietary software algorithm used to interpret the raw sensor
data is translated into apps that will allow real-time data
interpretation using the portable displays on smartphones, tablets
and laptops.
COPYRIGHT VANTAGE MHEALTHCARE 2015
26
Proprietary Technology
Co-Developed with NASA
Four Patents Issued and Two Pending
for this novel chemical sensing
nanotechnology
Vantage has the exclusive license for this
technology in human healthcare screenings
and for screenings of legal and illegal
narcotics which it obtained from its
majority shareholder Nanobeak
COPYRIGHT VANTAGE MHEALTHCARE 2015
27
Executive Management & Board Members
Steven R. Steinhubl, Chairman of the Board - Director of Digital medicine at Scripps Translational Science Institute and a practicing
cardiologist at the integrated Scripps Health System, San Diego
•
25 years in medicine; cardiologist; clinical researcher and former pharmaceutical company executive
•
Served as director of cardiovascular wellness and clinician-scientist with Geisinger Health System based in Danville, PA
•
US Air Force staff internist
Joseph C. Peters, President and Board Member - Former White House drug policy office’s acting deputy director for state and local affairs
under presidents Clinton and Bush
•
25 years of federal, state and local government experience and former Federal Prosecutor
•
Television and radio commentator for numerous major media outlets, providing expert insight on law enforcement investigative and counter
terrorism issues and technologies
Edward Rollins, Board Member - Senior advisor for Teneo, a global advisory firm that partners exclusively with CEOs and senior leaders of
many of the world's largest companies and organizations
•
Served in the administrations and advised four United States Presidents
•
He has advised heads of state and CEO’s of major corporations in foreign countries as well as CEO’s of Fortune 500 companies
•
Office of Political Affairs; White House Office of Intergovernmental Affairs and deputy chief of staff during the Reagan administration
Tony van Bijleveld, Board Member – General manager with drug manufacturer Patheon/DPX, a leading global provider of contract drug
development and manufacturing services
•
Previously general manager of Europe for Alliance Boots (100% owned by Walgreens) with responsibility for European operations and logistics
COPYRIGHT VANTAGE MHEALTHCARE 2015
28
Vantage mHealthcare, Inc.
Three Columbus Circle
15th Floor
New York, NY 10019
www.vantagemhealthcare.com
(OTCQB: VNTH)
Corporate Development Officer – Allison Swan – 818-261-5567
[email protected]
Vantage Banker and Corporate Advisor- Bill Clark – 626-975-3400
[email protected]
COPYRIGHT VANTAGE MHEALTHCARE 2015
29